Aptus Capital Advisors’s Biogen BIIB Stock Holding History

Aptus Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$250K	Sell	1,156 -132	-10%	-$25.3K	﹤0.01%	1022
2026 Q1	$236K	Sell	1,288 -280	-18%	-$51.6K	﹤0.01%	958
2025 Q4	$276K	Buy	+1,568	New	+$256K	﹤0.01%	918
2020 Q2	–	Sell	-8,826	Closed	-$2.79M	–	416
2020 Q1	$2.79M	Buy	8,826 +993	+13%	+$301K	0.24%	69
2019 Q4	$2.32M	Buy	7,833 +2,165	+38%	+$601K	0.16%	144
2019 Q3	$1.32M	Sell	5,668 -1,269	-18%	-$295K	0.07%	160
2019 Q2	$1.62M	Buy	6,937 +2,022	+41%	+$467K	0.23%	75
2019 Q1	$1.16M	Sell	4,915 -28	-0.6%	-$8.82K	0.2%	106
2018 Q4	$1.49M	Buy	+4,943	New	+$1.58M	0.39%	37

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aptus Capital Advisors's BIIB Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Biogen (BIIB) stake by 10% in Q2 2026, selling an estimated $25.3K and leaving 1,156 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Aptus Capital Advisors first reported a position in BIIB in Q4 2018 and has held it in 9 quarters since. The position peaked at $2.79M in Q1 2020. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Aptus Capital Advisors held 1,156 shares of Biogen worth $250K as of Q2 2026.
Aptus Capital Advisors sold 132 Biogen shares in Q2 2026, an estimated $25.3K.
Biogen made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1022 holding.
Aptus Capital Advisors first reported a position in Biogen in Q4 2018 and has held it in 9 quarters since.
Aptus Capital Advisors's Biogen position peaked at $2.79M in Q1 2020.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.